ERBB2 and bone metastasis: For the HER2‐zero group of 200 patients, the most frequent metastatic sites were bone, lung, and liver, in which there were 22 (11.0%) patients with bone metastasis, 15 (7.5%) patients with lung metastasis, and 10 (5.0%) patients with liver metastasis.